<p>Truffle Hound Capital LLC 在第二季度根據其最近向證券交易委員會提交的 13F 文件，收購了 InfuSystem Holdings, Inc. (NYSE:INFU - 免費報告) 的新頭寸。該公司收購了 180,000 股該公司的股票，價值約為 1,123,000 美元。Truffle Hound Capital LLC 在最近的報告期末持有 InfuSystem 約 0.88% 的股份。</p>
<ul>
<li>醫療設備的未來：你不能錯過的兩個強力買入</li>
</ul>
<p>其他一些機構投資者和對沖基金最近也調整了對該公司的持股。American Century Companies Inc. 在第一季度以約 256,000 美元的價格收購了 InfuSystem 的新頭寸。Voya Investment Management LLC 在第一季度以 182,000 美元的價格購買了 InfuSystem 的新頭寸。滙豐控股 PLC 在第一季度以 147,000 美元的價格收購了 InfuSystem 的新頭寸。Nuveen LLC 在第一季度以 465,000 美元的價格收購了 InfuSystem 的新頭寸。最後，Russell Investments Group Ltd. 在第一季度將其在 InfuSystem 的股份提高了 13.1%。Russell Investments Group Ltd. 目前持有 437,891 股該公司的股票，價值 2,356,000 美元，此前在上個季度又購買了 50,877 股。71.13% 的股票由機構投資者和對沖基金持有。</p>
<h2>分析師設定新目標價</h2>
<p>INFU 已成為幾份研究分析師報告的主題。Zacks Research 在 10 月 6 日的研究報告中將 InfuSystem 的股票評級從 “強力買入” 下調至 “持有”。Roth Capital 在 11 月 4 日的報告中重申了 “買入” 評級，並將 InfuSystem 的目標價上調至 14.00 美元（從 13.00 美元上調）。最後，Lake Street Capital 在 9 月 22 日的報告中開始覆蓋 InfuSystem。他們對該股票設定了 “買入” 評級和 15.00 美元的目標價。兩位投資分析師對該股票給予了強力買入評級，兩位給予了買入評級，一位給予了持有評級。根據 MarketBeat.com 的數據，InfuSystem 目前的共識評級為 “買入”，共識目標價為 14.50 美元。</p>
<p><strong>閲讀我們關於 INFU 的最新研究報告</strong></p>
<h2>內部交易活動</h2>
<p>在其他新聞中，董事 Scott Shuda 於 8 月 22 日星期五出售了 5,752 股該公司的股票。股票以平均價格 9.67 美元出售，總交易額為 55,621.84 美元。出售完成後，該董事直接持有 94,000 股該公司的股票，價值 908,980 美元。這代表了他們持股比例的 5.77% 的下降。該交易在向 SEC 提交的文件中披露，文件可在 SEC 網站上獲取。11.40% 的股票由內部人士持有。</p>
<h2>InfuSystem 股票下跌 2.0%</h2>
<p>NYSE INFU 週二開盤價為 9.32 美元。InfuSystem Holdings, Inc. 的 12 個月低點為 4.61 美元，12 個月高點為 11.04 美元。該公司的市值為 1.8953 億美元，市盈率為 155.36，貝塔值為 1.80。該公司的 50 日簡單移動平均線為 10.00 美元，200 日簡單移動平均線為 7.96 美元。該公司的債務與股本比率為 0.50，流動比率為 1.98，速動比率為 1.59。</p>
<h2>關於 InfuSystem</h2>
<p>(免費報告)</p>
<p>InfuSystem Holdings, Inc. 通過其子公司在美國和加拿大提供輸液泵及相關產品和服務。該公司分為兩個部門，患者服務和設備解決方案。它向腫瘤科、輸液和醫院門診化療診所提供電子便攜式輸液泵及相關一次性供應包，用於治療各種癌症，包括結直腸癌、疼痛管理和其他疾病狀態。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 InfuSystem</li>
<li>股票拆分，真的會影響投資者嗎？</li>
<li>隨着 AI 驅動存儲需求，Seagate 股票可能飆升</li>
<li>國會股票交易跟蹤</li>
<li>惠而浦的最壞時刻可能已經過去——未來有機會</li>
<li>你應該投資於便士股票嗎？</li>
<li>這三隻被打壓的股票可能是你本季度最佳的購買機會</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUlORlU?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUlORlU"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 InfuSystem 嗎？</h2>
<p>在你考慮 InfuSystem 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議現在購買，以便在更廣泛的市場注意到之前... 而 InfuSystem 並不在名單上。</p>
<p>雖然 InfuSystem 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

InfuSystems控股

<p>根據向美國證券交易委員會（SEC）提交的 13F 文件，Truffle Hound Capital LLC 在第二季度收購了 180,000 股 InfuSystem Holdings, Inc.，價值約為 1,123,000 美元。這次收購代表了 InfuSystem 約 0.88% 的股份。該公司在美國和加拿大提供輸液泵及相關服務。分析師對 InfuSystem 的共識評級為 “買入”，目標價格為 14.50 美元</p>

<p>Truffle Hound Capital LLC acquired a new position in shares of InfuSystem Holdings, Inc. (NYSE:INFU - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities &amp; Exchange Commission. The firm acquired 180,000 shares of the company's stock, valued at approximately $1,123,000. Truffle Hound Capital LLC owned about 0.88% of InfuSystem at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Truffle Hound Capital LLC 在第二季度根據其最近向證券交易委員會提交的 13F 文件，收購了 InfuSystem Holdings, Inc. (NYSE:INFU - 免費報告) 的新頭寸。該公司收購了 180,000 股該公司的股票，價值約為 1,123,000 美元。Truffle Hound Capital LLC 在最近的報告期末持有 InfuSystem 約 0.88% 的股份。</p>
</div><ul>
<li>The Future of Medical Devices: Two Strong Buys You Can't Miss</li>
</ul>
<div class="lb-trans"><ul>
<li>醫療設備的未來：你不能錯過的兩個強力買入</li>
</ul>
</div><p>A number of other institutional investors and hedge funds also recently modified their holdings of the business. American Century Companies Inc. acquired a new position in InfuSystem during the 1st quarter valued at about $256,000. Voya Investment Management LLC bought a new position in shares of InfuSystem in the first quarter worth $182,000. Hsbc Holdings PLC acquired a new position in shares of InfuSystem during the first quarter valued at $147,000. Nuveen LLC acquired a new position in shares of InfuSystem during the first quarter valued at $465,000. Finally, Russell Investments Group Ltd. raised its stake in shares of InfuSystem by 13.1% during the first quarter. Russell Investments Group Ltd. now owns 437,891 shares of the company's stock valued at $2,356,000 after purchasing an additional 50,877 shares in the last quarter. 71.13% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他一些機構投資者和對沖基金最近也調整了對該公司的持股。American Century Companies Inc. 在第一季度以約 256,000 美元的價格收購了 InfuSystem 的新頭寸。Voya Investment Management LLC 在第一季度以 182,000 美元的價格購買了 InfuSystem 的新頭寸。滙豐控股 PLC 在第一季度以 147,000 美元的價格收購了 InfuSystem 的新頭寸。Nuveen LLC 在第一季度以 465,000 美元的價格收購了 InfuSystem 的新頭寸。最後，Russell Investments Group Ltd. 在第一季度將其在 InfuSystem 的股份提高了 13.1%。Russell Investments Group Ltd. 目前持有 437,891 股該公司的股票，價值 2,356,000 美元，此前在上個季度又購買了 50,877 股。71.13% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>INFU has been the topic of several research analyst reports. Zacks Research cut shares of InfuSystem from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Monday, October 6th. Roth Capital reiterated a &#34;buy&#34; rating and issued a $14.00 price objective (up from $13.00) on shares of InfuSystem in a report on Tuesday, November 4th. Finally, Lake Street Capital began coverage on InfuSystem in a report on Monday, September 22nd. They set a &#34;buy&#34; rating and a $15.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat.com, InfuSystem presently has a consensus rating of &#34;Buy&#34; and a consensus price target of $14.50.</p>
<div class="lb-trans"><p>INFU 已成為幾份研究分析師報告的主題。Zacks Research 在 10 月 6 日的研究報告中將 InfuSystem 的股票評級從 “強力買入” 下調至 “持有”。Roth Capital 在 11 月 4 日的報告中重申了 “買入” 評級，並將 InfuSystem 的目標價上調至 14.00 美元（從 13.00 美元上調）。最後，Lake Street Capital 在 9 月 22 日的報告中開始覆蓋 InfuSystem。他們對該股票設定了 “買入” 評級和 15.00 美元的目標價。兩位投資分析師對該股票給予了強力買入評級，兩位給予了買入評級，一位給予了持有評級。根據 MarketBeat.com 的數據，InfuSystem 目前的共識評級為 “買入”，共識目標價為 14.50 美元。</p>
</div><p><strong>Read Our Latest Research Report on INFU</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 INFU 的最新研究報告</strong></p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部交易活動</h2>
</div><p>In other news, Director Scott Shuda sold 5,752 shares of the company's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $9.67, for a total transaction of $55,621.84. Following the completion of the sale, the director directly owned 94,000 shares of the company's stock, valued at $908,980. This represents a 5.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 11.40% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他新聞中，董事 Scott Shuda 於 8 月 22 日星期五出售了 5,752 股該公司的股票。股票以平均價格 9.67 美元出售，總交易額為 55,621.84 美元。出售完成後，該董事直接持有 94,000 股該公司的股票，價值 908,980 美元。這代表了他們持股比例的 5.77% 的下降。該交易在向 SEC 提交的文件中披露，文件可在 SEC 網站上獲取。11.40% 的股票由內部人士持有。</p>
</div><h2>InfuSystem Stock Down 2.0%</h2>
<div class="lb-trans"><h2>InfuSystem 股票下跌 2.0%</h2>
</div><p>NYSE INFU opened at $9.32 on Tuesday. InfuSystem Holdings, Inc. has a 12 month low of $4.61 and a 12 month high of $11.04. The company has a market capitalization of $189.53 million, a P/E ratio of 155.36 and a beta of 1.80. The company's 50 day simple moving average is $10.00 and its 200 day simple moving average is $7.96. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.98 and a quick ratio of 1.59.</p>
<div class="lb-trans"><p>NYSE INFU 週二開盤價為 9.32 美元。InfuSystem Holdings, Inc. 的 12 個月低點為 4.61 美元，12 個月高點為 11.04 美元。該公司的市值為 1.8953 億美元，市盈率為 155.36，貝塔值為 1.80。該公司的 50 日簡單移動平均線為 10.00 美元，200 日簡單移動平均線為 7.96 美元。該公司的債務與股本比率為 0.50，流動比率為 1.98，速動比率為 1.59。</p>
</div><h2>About InfuSystem</h2>
<div class="lb-trans"><h2>關於 InfuSystem</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免費報告)</p>
</div><p>InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.</p>
<div class="lb-trans"><p>InfuSystem Holdings, Inc. 通過其子公司在美國和加拿大提供輸液泵及相關產品和服務。該公司分為兩個部門，患者服務和設備解決方案。它向腫瘤科、輸液和醫院門診化療診所提供電子便攜式輸液泵及相關一次性供應包，用於治療各種癌症，包括結直腸癌、疼痛管理和其他疾病狀態。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than InfuSystem</li>
<li>Stock Splits, Do They Really Impact Investors?</li>
<li>Seagate Stock Could Soar as AI Drives Storage Demand</li>
<li>Following Congress Stock Trades</li>
<li>Whirlpool’s Worst May Be Over—Upside Opportunity Ahead</li>
<li>Should You Invest in Penny Stocks?</li>
<li>These 3 Beaten-Down Stocks Could Be Your Best Buying Opportunity This Quarter</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 InfuSystem</li>
<li>股票拆分，真的會影響投資者嗎？</li>
<li>隨着 AI 驅動存儲需求，Seagate 股票可能飆升</li>
<li>國會股票交易跟蹤</li>
<li>惠而浦的最壞時刻可能已經過去——未來有機會</li>
<li>你應該投資於便士股票嗎？</li>
<li>這三隻被打壓的股票可能是你本季度最佳的購買機會</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUlORlU" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=INFU"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in InfuSystem Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 InfuSystem 嗎？</h2>
</div><p>Before you consider InfuSystem, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 InfuSystem 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InfuSystem wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議現在購買，以便在更廣泛的市場注意到之前... 而 InfuSystem 並不在名單上。</p>
</div><p>While InfuSystem currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 InfuSystem 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Truffle Hound Capital LLC 購入了 InfuSystem Holdings, Inc.的新股份